Pour faire avancer le traitement des maladies rares ensemble

EspeRare et Genetic Alliance développent GaugeRx

10juin

 GaugeRx, un nouvel outil digital d'évaluation est en développement pour accélérer le développement de médicaments pour les maladies rares.

WASHINGTON, DC – June 10, 2013 – The EspeRare Foundation of Geneva, Switzerland and Genetic Alliance of Washington, DC announced a collaboration to streamline the process of translating research into health outcomes by strengthening the decision-making for drug development. The collaboration will result in a dynamic, web-based analytics and assessment tool that integrates and translates vast amount of knowledge about human health and disease to support drug (re)positioning and development decision-making for a broad range of healthcare stakeholders, from pharmaceutical companies to advocacy groups.

Read the full press release here